Bausch Health Companies Inc (BHC)

$6.21

+0.02

(+0.32%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $6.13
    $6.33
    $6.21
    downward going graph

    1.37%

    Downside

    Day's Volatility :3.16%

    Upside

    1.82%

    downward going graph
  • $3.96
    $11.46
    $6.21
    downward going graph

    36.23%

    Downside

    52 Weeks Volatility :65.45%

    Upside

    45.81%

    downward going graph

Returns

PeriodBausch Health Companies IncSector (Health Care)Index (Russel 2000)
3 Months
-0.96%
5.1%
0.0%
6 Months
-33.08%
4.9%
0.0%
1 Year
-26.25%
16.6%
0.0%
3 Years
-78.75%
13.2%
-22.3%

Highlights

Market Capitalization
2.3B
Book Value
- $3.2
Earnings Per Share (EPS)
-1.29
PEG Ratio
0.63
Wall Street Target Price
7.64
Profit Margin
-5.12%
Operating Margin TTM
17.6%
Return On Assets TTM
4.16%
Return On Equity TTM
-2304.54%
Revenue TTM
9.2B
Revenue Per Share TTM
25.1
Quarterly Revenue Growth YOY
10.9%
Gross Profit TTM
5.8B
EBITDA
3.0B
Diluted Eps TTM
-1.29
Quarterly Earnings Growth YOY
-0.61
EPS Estimate Current Year
3.61
EPS Estimate Next Year
4.16
EPS Estimate Current Quarter
0.88
EPS Estimate Next Quarter
1.04

Analyst Recommendation

Hold
    0
    0%Buy
    60%Hold
    40%Sell
Based on 10 Wall street analysts offering stock ratings for Bausch Health Companies Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
4
4
Hold
6
4
4
Sell
4
00
00

Analyst Forecast

What analysts predicted

Upside of 23.03%

Current $6.21
Target $7.64

Company Financials

FY18Y/Y Change
Revenue
8.4B
↓ 3.94%
Net Income
-4.1B
↓ 272.55%
Net Profit Margin
-49.5%
↓ 77.06%
FY19Y/Y Change
Revenue
8.6B
↑ 2.64%
Net Income
-1.8B
↓ 57.02%
Net Profit Margin
-20.73%
↑ 28.77%
FY20Y/Y Change
Revenue
8.0B
↓ 6.67%
Net Income
-559.0M
↓ 68.65%
Net Profit Margin
-6.96%
↑ 13.77%
FY21Y/Y Change
Revenue
8.4B
↑ 5.07%
Net Income
-937.0M
↑ 67.62%
Net Profit Margin
-11.11%
↓ 4.15%
FY22Y/Y Change
Revenue
8.1B
↓ 3.68%
Net Income
-212.0M
↓ 77.37%
Net Profit Margin
-2.61%
↑ 8.5%
FY23Y/Y Change
Revenue
8.8B
↑ 7.79%
Net Income
-592.0M
↑ 179.25%
Net Profit Margin
-6.76%
↓ 4.15%
Q1 FY23Q/Q Change
Revenue
1.9B
↓ 11.35%
Net Income
-209.0M
↓ 49.02%
Net Profit Margin
-10.75%
↑ 7.95%
Q2 FY23Q/Q Change
Revenue
2.2B
↑ 11.47%
Net Income
26.0M
↓ 112.44%
Net Profit Margin
1.2%
↑ 11.95%
Q3 FY23Q/Q Change
Revenue
2.2B
↑ 3.28%
Net Income
-378.0M
↓ 1553.85%
Net Profit Margin
-16.89%
↓ 18.09%
Q4 FY23Q/Q Change
Revenue
2.4B
↑ 7.6%
Net Income
395.0M
↓ 204.5%
Net Profit Margin
16.4%
↑ 33.29%
Q1 FY24Q/Q Change
Revenue
2.1B
↓ 10.99%
Net Income
-63.7M
↓ 116.13%
Net Profit Margin
-2.97%
↓ 19.37%
Q2 FY24Q/Q Change
Revenue
2.4B
↑ 12.09%
Net Income
10.0M
↓ 115.7%
Net Profit Margin
0.42%
↑ 3.39%
FY18Y/Y Change
Total Assets
27.4B
↓ 26.8%
Total Liabilities
24.6B
↓ 21.93%
FY19Y/Y Change
Total Assets
33.9B
↑ 23.38%
Total Liabilities
32.7B
↑ 32.86%
FY20Y/Y Change
Total Assets
31.2B
↓ 7.87%
Total Liabilities
30.6B
↓ 6.52%
FY21Y/Y Change
Total Assets
29.2B
↓ 6.4%
Total Liabilities
29.2B
↓ 4.44%
FY22Y/Y Change
Total Assets
25.7B
↓ 12.04%
Total Liabilities
25.4B
↓ 13.03%
FY23Y/Y Change
Total Assets
27.4B
↑ 6.48%
Total Liabilities
27.4B
↑ 7.89%
Q1 FY23Q/Q Change
Total Assets
25.4B
↓ 0.94%
Total Liabilities
25.3B
↓ 0.5%
Q2 FY23Q/Q Change
Total Assets
33.8B
↑ 32.82%
Total Liabilities
33.4B
↑ 32.16%
Q3 FY23Q/Q Change
Total Assets
27.1B
↓ 19.92%
Total Liabilities
27.3B
↓ 18.36%
Q4 FY23Q/Q Change
Total Assets
27.4B
↑ 1.06%
Total Liabilities
27.4B
↑ 0.49%
Q1 FY24Q/Q Change
Total Assets
26.9B
↓ 1.7%
Total Liabilities
27.1B
↓ 1.36%
Q2 FY24Q/Q Change
Total Assets
26.5B
↓ 1.47%
Total Liabilities
26.7B
↓ 1.26%
FY18Y/Y Change
Operating Cash Flow
1.5B
↓ 34.45%
Investing Cash Flow
-196.0M
↓ 106.79%
Financing Cash Flow
-1.4B
↓ 72.74%
FY19Y/Y Change
Operating Cash Flow
1.5B
↑ 0.0%
Investing Cash Flow
-419.0M
↑ 113.78%
Financing Cash Flow
1.4B
↓ 206.65%
FY20Y/Y Change
Operating Cash Flow
1.1B
↓ 25.98%
Investing Cash Flow
-261.0M
↓ 37.71%
Financing Cash Flow
-2.3B
↓ 258.97%
FY21Y/Y Change
Operating Cash Flow
1.4B
↑ 28.35%
Investing Cash Flow
409.0M
↓ 256.7%
Financing Cash Flow
-1.5B
↓ 34.05%
FY22Y/Y Change
Operating Cash Flow
-728.0M
↓ 151.05%
Investing Cash Flow
-303.0M
↓ 174.08%
Financing Cash Flow
-474.0M
↓ 68.67%
Q1 FY23Q/Q Change
Operating Cash Flow
154.0M
↓ 67.58%
Investing Cash Flow
-78.0M
↓ 74.26%
Financing Cash Flow
-142.0M
↓ 48.55%
Q2 FY23Q/Q Change
Operating Cash Flow
268.8M
↑ 74.53%
Investing Cash Flow
-30.0M
↓ 61.54%
Financing Cash Flow
-120.0M
↓ 15.49%
Q3 FY23Q/Q Change
Operating Cash Flow
282.0M
↑ 4.92%
Investing Cash Flow
-2.0B
↑ 6556.67%
Financing Cash Flow
1.8B
↓ 1613.33%

Technicals Summary

Sell

Neutral

Buy

Bausch Health Companies Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bausch Health Companies Inc
Bausch Health Companies Inc
18.97%
-33.08%
-26.25%
-78.75%
-71.89%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-16.62%
-11.2%
10.78%
28.21%
20.17%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.49%
20.82%
28.48%
39.41%
39.41%
Zoetis Inc.
Zoetis Inc.
2.41%
4.25%
0.77%
-8.94%
49.4%
Viatris Inc.
Viatris Inc.
-0.79%
-8.6%
12.7%
-23.12%
-31.03%
Catalent, Inc.
Catalent, Inc.
0.82%
6.48%
22.57%
-57.47%
16.16%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bausch Health Companies Inc
Bausch Health Companies Inc
71.75
NA
0.63
3.61
-23.05
0.04
NA
-3.2
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
36.53
36.53
0.27
4.57
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
33.32
33.32
1.47
0.39
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
36.6
36.6
2.61
5.82
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.68
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.87
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bausch Health Companies Inc
Bausch Health Companies Inc
Hold
$2.3B
-71.89%
71.75
-5.12%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.2B
20.17%
36.53
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$47.1B
39.41%
33.32
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$85.7B
49.4%
36.6
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.5B
-31.03%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$10.9B
16.16%
211.02
-23.81%

Insights on Bausch Health Companies Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.14B → 2.40B (in $), with an average increase of 10.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -63.71M → 10.0M (in $), with an average increase of 737.1% per quarter

  • Vs HLN

    In the last 1 year, Haleon Plc Spon Ads has given 28.5% return, outperforming this stock by 54.7%

Institutional Holdings

  • ICAHN CARL C

    9.46%

  • Paulson & Company Inc

    7.20%

  • Goldentree Asset Management LP

    6.11%

  • Nomura Holdings Inc

    4.19%

  • HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND

    3.54%

  • Hudson Bay Capital Management LP

    3.13%

Company Information

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###

Organization
Bausch Health Companies Inc
Employees
20270
CEO
Mr. Thomas J. Appio
Industry
Health Technology

Discover More

FAQs